Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old

International Urology and Nephrology

Volumn 44, Issue 6, 2012, Pages 1697-1703

  Miyake, Hideaki ^a   Sakai, Iori ^a   Harada, Ken Ichi ^a   Muramaki, Mototsugu ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Castration resistant prostate cancer; Docetaxel; Elderly patients

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; TAXOID;

AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; GERIATRIC PATIENT; HUMAN; JAPANESE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; ASIAN; DRUG RESISTANCE; METASTASIS; PATHOLOGY; PROSTATE TUMOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 84877612537     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-012-0223-z     Document Type: Article

References (20)

1. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, Sobue T (2011) Cancer incidence and incidence rates in Japan in 2005: based on data from 12 population-based cancer registries in the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 41:139-147
2. Cancer Registration Committee of the Japanese Urological Association (2005) Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. Int J Urol 12:46-61
3. Donkena KV, Yuan H, Young CY (2010) Recent advances in understanding hormonal therapy resistant prostate cancer. Curr Cancer Drug Targets 10:402-410
4. Beltran H, Beer TM, Carducci MA, et al. (2011) New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol 60:279-290
5. Droz JP, Balducci L, Bolla M, et al. (2010) Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 106:462-469
6. Tannock IF, de Wit R, Berry WR, et al. (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
7. Petrylak DP, Tangen CM, Hussain MH, et al. (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
8. Ide H, Kikuchi E, Kono H, et al. (2010) Docetaxel in combination with prednisolone for hormone refractory prostate cancer. Jpn J Clin Oncol 40:79-84
9. Matsumoto A, Inoue A, Yokoi S, et al. (2009) Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer. Int J Urol 16:687-691
10. Naito S, Tsukamoto T, Koga H, et al. (2008) Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter phase II trial in Japan. Jpn J Clin Oncol 38:365-372
11. Takaha N, Okihara K, Kamoi K, et al. (2011) Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer. Urol Int 87:263-269
12. Italiano A, Ortholan C, Oudard S, et al. (2009) Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol 55:1368-1375
13. Takechi H, Ito K, Yamamoto T, Miyakubo M, Ohi M, Suzuki K (2008) Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan. Urology 72:1111-1115
14. Maekawa K, Harakawa N, Yoshimura T, et al. (2010) CYP3A416 and CYP3A418 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos 38:2100-2104
15. Misumi T, Yamamoto Y, Murakami T, et al. (2010) Genetic alterations at 13q14 may correlate with differences in the biological behavior of prostate cancer between Japanese and Caucasian men. Urol Int 84:461-466
16. Phan VH, Moore MM, McLachlan AJ, Piquette-Miller M, Xu H, Clarke SJ (2009) Ethnic differences in drug metabolism and toxicity from chemotherapy. Expert Opin Drug Metab Toxicol 5:243-257
17. Miyake H, Sakai I, Terakawa T, Harada KI, Fujisawa M. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer. Urol Oncol (in press)
18. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M (2007) A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 13:6396-6403
19. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S (2010) The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 46:517-525
20. ten Tije AJ, Verweij J, Carducci MA, et al. (2005) Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 23:1070-1077